Healthy Nevada Project Sharing Clinical Results with Consenting Participants
02. Oktober 2018 08:00 ET
|
Renown Health
Reno, Nev., Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Healthy Nevada Project led by Renown Institute for Health Innovation (Renown IHI) is announcing another landmark milestone – returning clinical...
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
08. Mai 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2018 financial results. During the first quarter, the Company...
Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196
13. März 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
- MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β -selective agonist that is being developed for patients with non-alcoholic steatohepatitis (NASH) and...
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
08. Februar 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
-- Statistically significant improvement achieved in the reduction of LDL cholesterol (LDL-C) with MGL-3196 compared to placebo, the primary endpoint of this 12-week Phase 2 clinical trial in HeFH...
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
18. Dezember 2017 23:26 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
18. Dezember 2017 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results
09. November 2017 07:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Penn., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2017 financial results and several clinical accomplishments that...
Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting
23. Oktober 2017 07:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today presented preclinical results for MGL-3196 in a poster session at The Liver Meeting® 2017,...
Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
24. September 2017 08:00 ET
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of...
Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
19. September 2017 07:30 ET
|
Madrigal Pharmaceuticals, Inc.
-- Second DSMB review includes data from both Phase 2 studies in NASH and HeFH -- -- Top-line results from NASH expected late 2017 and HeFH early 2018 -- CONSHOHOCKEN, Pa., Sept. 19, 2017 (GLOBE...